Plasma Citrulline Level in Relation to Absorptive Surface

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University Hospital, Ghent
ClinicalTrials.gov Identifier:
NCT00286039
First received: February 1, 2006
Last updated: September 29, 2011
Last verified: September 2011
  Purpose

Correlation between determination of citrulline in plasma or dried blood

Reference ranges for healthy children and babies

Longitudinal follow-up of citrulline in preterm babies


Condition Intervention
Intestinal "Failure"
Procedure: Blood sampling

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Plasma Citrulline Level in Relation to Absorptive Surface

Further study details as provided by University Hospital, Ghent:

Primary Outcome Measures:
  • Correlation between determination of citrulline in plasma or dried blood [ Time Frame: Untill end of study ] [ Designated as safety issue: No ]
  • Reference ranges for healthy children and babies [ Time Frame: Until end of study ] [ Designated as safety issue: No ]
  • Longitudinal follow-up of citrulline in preterm babies [ Time Frame: Untill end of study ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: August 2005
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Blood sampling
    Blood sampling is used.
  Eligibility

Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 0-18 years
  • preterm babies up to 1.500g
  • preterm babies over 1.500g

Exclusion Criteria:

  • gastro-intestinal problems (except for the preterm babies)
  • congenital metabolic disorders
  • dysfunction of the liver or kidneys
  • congenital defects
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00286039

Locations
Belgium
University Hospital Ghent
Ghent, Belgium, 9000
Sponsors and Collaborators
University Hospital, Ghent
Investigators
Principal Investigator: Eddy Robberecht, MD, PhD University Hospital, Ghent
  More Information

Additional Information:
No publications provided

Responsible Party: University Hospital, Ghent
ClinicalTrials.gov Identifier: NCT00286039     History of Changes
Other Study ID Numbers: 2005/163
Study First Received: February 1, 2006
Last Updated: September 29, 2011
Health Authority: Belgium: Institutional Review Board

ClinicalTrials.gov processed this record on July 10, 2014